<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470118</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-LAS-011-001</org_study_id>
    <nct_id>NCT01470118</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to
      artificial tears (placebo) in the prevention of ocular itching associated with allergic
      conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16</measure>
    <time_frame>Day 0 Hour 16</time_frame>
    <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 0 (Visit 3) at hour 16. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Conjunctival redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored conjunctival redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less conjunctival redness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Ciliary redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored ciliary redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less ciliary redness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Episcleral redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored episcleral redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less episcleral redness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Chemosis evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored chemosis on a numeric analog scale ranging from 0=None to 4=Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less chemosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Eyelid swelling evaluated by the subject at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored eyelid swelling on a numeric analog 4-point scale ranging from 0=None to 3=Severe. For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less lid swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</measure>
    <time_frame>Day 14 Hour 24</time_frame>
    <description>Tearing evaluated by the subject at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored tearing on a 5-point numeric analog scale ranging from 0=None/Normal to 4=Very Severe. For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less tearing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>LASTACAFT® (alcaftadine 0.25%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pataday™ (olopatadine 0.2%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alcaftadine 0.25% ophthalmic solution</intervention_name>
    <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
    <arm_group_label>LASTACAFT® (alcaftadine 0.25%)</arm_group_label>
    <other_name>LASTACAFT®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olopatadine 0.2% ophthalmic solution</intervention_name>
    <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
    <arm_group_label>Pataday™ (olopatadine 0.2%)</arm_group_label>
    <other_name>Pataday™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%</intervention_name>
    <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
    <arm_group_label>Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)</arm_group_label>
    <other_name>Tears Naturale® II Artificial Tears</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of eye allergies within the past 24 months

          -  Willing to not wear contact lenses at least 72 hours prior to the study start and
             during the study period

        Exclusion Criteria:

          -  Current eye infection

          -  Eye surgery within 3 months or vision correction surgery within 6 months

          -  Any planned surgery during the study or 30 days after the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <results_first_submitted>December 13, 2012</results_first_submitted>
  <results_first_submitted_qc>January 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Alcaftadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LASTACAFT® (Alcaftadine 0.25%)</title>
          <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="P2">
          <title>Pataday™ (Olopatadine 0.2%)</title>
          <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
          <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LASTACAFT® (Alcaftadine 0.25%)</title>
          <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="B2">
          <title>Pataday™ (Olopatadine 0.2%)</title>
          <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
          <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="12.44"/>
                    <measurement group_id="B2" value="37.0" spread="14.84"/>
                    <measurement group_id="B3" value="39.3" spread="12.31"/>
                    <measurement group_id="B4" value="38.5" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16</title>
        <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 0 (Visit 3) at hour 16. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.</description>
        <time_frame>Day 0 Hour 16</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16</title>
          <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 0 (Visit 3) at hour 16. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.716"/>
                    <measurement group_id="O2" value="1.01" spread="0.8211"/>
                    <measurement group_id="O3" value="2.14" spread="0.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.789"/>
                    <measurement group_id="O2" value="1.13" spread="0.852"/>
                    <measurement group_id="O3" value="2.35" spread="0.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.830"/>
                    <measurement group_id="O2" value="1.12" spread="0.824"/>
                    <measurement group_id="O3" value="2.20" spread="0.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Conjunctival redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored conjunctival redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less conjunctival redness.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Conjunctival redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored conjunctival redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less conjunctival redness.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.612"/>
                    <measurement group_id="O2" value="1.78" spread="0.709"/>
                    <measurement group_id="O3" value="2.08" spread="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.672"/>
                    <measurement group_id="O2" value="2.01" spread="0.805"/>
                    <measurement group_id="O3" value="2.22" spread="0.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.652"/>
                    <measurement group_id="O2" value="1.92" spread="0.870"/>
                    <measurement group_id="O3" value="2.20" spread="0.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Ciliary redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored ciliary redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less ciliary redness.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Ciliary redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored ciliary redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less ciliary redness.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.730"/>
                    <measurement group_id="O2" value="1.47" spread="0.773"/>
                    <measurement group_id="O3" value="1.83" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.805"/>
                    <measurement group_id="O2" value="1.67" spread="0.901"/>
                    <measurement group_id="O3" value="2.00" spread="0.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.754"/>
                    <measurement group_id="O2" value="1.65" spread="0.909"/>
                    <measurement group_id="O3" value="1.94" spread="0.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Episcleral redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored episcleral redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less episcleral redness.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Episcleral redness evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored episcleral redness on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less episcleral redness.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.667"/>
                    <measurement group_id="O2" value="1.56" spread="0.827"/>
                    <measurement group_id="O3" value="2.01" spread="0.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.649"/>
                    <measurement group_id="O2" value="1.82" spread="0.924"/>
                    <measurement group_id="O3" value="2.15" spread="0.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.645"/>
                    <measurement group_id="O2" value="1.79" spread="0.960"/>
                    <measurement group_id="O3" value="2.13" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Chemosis evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored chemosis on a numeric analog scale ranging from 0=None to 4=Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less chemosis.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Chemosis evaluated by the investigator at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Investigators scored chemosis on a numeric analog scale ranging from 0=None to 4=Severe (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less chemosis.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.392"/>
                    <measurement group_id="O2" value="0.97" spread="0.479"/>
                    <measurement group_id="O3" value="1.15" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.403"/>
                    <measurement group_id="O2" value="1.09" spread="0.616"/>
                    <measurement group_id="O3" value="1.34" spread="0.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.457"/>
                    <measurement group_id="O2" value="1.13" spread="0.677"/>
                    <measurement group_id="O3" value="1.42" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Eyelid swelling evaluated by the subject at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored eyelid swelling on a numeric analog 4-point scale ranging from 0=None to 3=Severe. For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less lid swelling.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Eyelid swelling evaluated by the subject at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored eyelid swelling on a numeric analog 4-point scale ranging from 0=None to 3=Severe. For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less lid swelling.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.62"/>
                    <measurement group_id="O2" value="0.4" spread="0.51"/>
                    <measurement group_id="O3" value="1.0" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.66"/>
                    <measurement group_id="O2" value="0.6" spread="0.74"/>
                    <measurement group_id="O3" value="1.0" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.65"/>
                    <measurement group_id="O2" value="0.6" spread="0.77"/>
                    <measurement group_id="O3" value="1.1" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Tearing evaluated by the subject at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored tearing on a 5-point numeric analog scale ranging from 0=None/Normal to 4=Very Severe. For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less tearing.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Tearing evaluated by the subject at 7, 15, and 20 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored tearing on a 5-point numeric analog scale ranging from 0=None/Normal to 4=Very Severe. For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less tearing.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.49"/>
                    <measurement group_id="O2" value="0.4" spread="0.81"/>
                    <measurement group_id="O3" value="1.0" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.62"/>
                    <measurement group_id="O2" value="0.6" spread="0.93"/>
                    <measurement group_id="O3" value="0.9" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.60"/>
                    <measurement group_id="O2" value="0.6" spread="1.03"/>
                    <measurement group_id="O3" value="0.8" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24</title>
        <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.</description>
        <time_frame>Day 14 Hour 24</time_frame>
        <population>Intent-to-Treat: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>LASTACAFT® (Alcaftadine 0.25%)</title>
            <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Pataday™ (Olopatadine 0.2%)</title>
            <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
            <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24</title>
          <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 14 (Visit 4) at hour 24. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.</description>
          <population>Intent-to-Treat: All randomized subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.807"/>
                    <measurement group_id="O2" value="0.97" spread="0.771"/>
                    <measurement group_id="O3" value="2.27" spread="0.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.851"/>
                    <measurement group_id="O2" value="1.16" spread="0.886"/>
                    <measurement group_id="O3" value="2.19" spread="0.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.911"/>
                    <measurement group_id="O2" value="1.01" spread="0.932"/>
                    <measurement group_id="O3" value="1.96" spread="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population was defined as all randomized subjects who received at least one dose of study treatment and was used to assess adverse events (AEs) and serious adverse events (SAEs).</desc>
      <group_list>
        <group group_id="E1">
          <title>LASTACAFT® (Alcaftadine 0.25%)</title>
          <description>One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="E2">
          <title>Pataday™ (Olopatadine 0.2%)</title>
          <description>One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)</title>
          <description>One drop of placebo instilled in each eye at Day 0 and Day 14.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

